1. Lerman, A, Zeiher, AM. Endothelial function: cardiac events. Circulation 2005; 111: 363–368.
2. Fischer, D, Rossa, S, Landmesser, U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26: 65–69.
3. Engelfriet, P, Boersma, E, Oechslin, E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325–2333.
4. Ammash, N, Warnes, CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28: 768–772.
5. Daliento, L, Somerville, J, Presbitero, P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845–1855.
6. Perloff, JK, Hart, EM, Greaves, SM, Miner, PD, Child, JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92: 182–187.
7. Silversides, CK, Granton, JT, Konen, E, Hart, MA, Webb, GD, Therrien, J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42: 1982–1987.
8. Niwa, K, Perloff, JK, Kaplan, S, Child, JS, Miner, PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34: 223–232.
9. Oechslin, EN, Harrison, DA, Connelly, MS, Webb, GD, Siu, SC. Mode of death in adults with congenital heart disease. Am J Cardiol 2000; 86: 1111–1116.
10. Pirofsky, B. The determination of blood viscosity in man by a method based on Poiseuille’s law. J Clin Invest 1953; 32: 292–298.
11. Stuart, J, Kenny, MW. Blood rheology. J Clin Pathol 1980; 33: 417–429.
12. House, SD, Lipowsky, HH. Microvascular hematocrit and red cell flux in rat cremaster muscle. Am J Physiol 1987; 252 (Part 2): H211–H222.
13. Lipowsky, HH, Firrell, JC. Microvascular hemodynamics during systemic hemodilution and hemoconcentration. Am J Physiol 1986; 250 (Part 2): H908–H922.
14. Fahraeus, R. The suspension stability of blood. Physiol Rev 1929; 9: 241–274.
15. Lipowsky, HH, Usami, S, Chien, S. In vivo measurements of “apparent viscosity” and microvessel hematocrit in the mesentery of the cat. Microvasc Res 1980; 19: 297–319.
16. Barbee, JH, Cokelet, GR. Prediction of blood flow in tubes with diameters as small as 29 microns. Microvasc Res 1971; 3: 17–21.
17. Pries, AR, Neuhaus, D, Gaehtgens, P. Blood viscosity in tube flow: dependence on diameter and hematocrit. Am J Physiol 1992; 263 (Part 2): H1770–H1778.
18. Pries, AR, Secomb, TW. Microvascular blood viscosity in vivo and the endothelial surface layer. Am J Physiol Heart Circ Physiol 2005; 289: H2657–H2664.
19. Linderkamp, O, Klose, HJ, Betke, K, et al. Increased blood viscosity in patients with cyanotic congenital heart disease and iron deficiency. J Pediatr 1979; 95: 567–569.
20. Hutton, RD. The effect of iron deficiency on whole blood viscosity in polycythaemic patients. Br J Haematol 1979; 43: 191–199.
21. Milligan, DW, MacNamee, R, Roberts, BE, Davies, JA. The influence of iron-deficient indices on whole blood viscosity in polycythaemia. Br J Haematol 1982; 50: 467–471.
22. Pearson, TC, Grimes, AJ, Slater, NG, Wetherley-Mein, G. Viscosity and iron deficiency in treated polycythaemia. Br J Haematol 1981; 49: 123–127.
23. Van de Pette, JE, Guthrie, DL, Pearson, TC. Whole blood viscosity in polycythaemia: the effect of iron deficiency at a range of haemoglobin and packed cell volumes. Br J Haematol 1986; 63: 369–375.
24. Broberg, CS, Bax, BE, Okonko, DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48: 356–365.
25. Iolster, NJ. Blood coagulation in children with cyanotic congenital heart disease. Acta Paediatr Scand 1970; 59: 551–557.
26. Martelle, RR, Linde, LM. Cerebrovascular accidents with tetralogy of Fallot. Am J Dis Child 1961; 101: 206–209.
27. Maguire, JL, deVeber, G, Parkin, PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics 2007; 120: 1053–1057.
28. Koller, A, Sun, D, Kaley, G. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res 1993; 72: 1276–1284.
29. Tsai, AG, Friesenecker, B, McCarthy, M, Sakai, H, Intaglietta, M. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. Am J Physiol 1998; 275 (Part 2): H2170–H2180.
30. Hudak, ML, Jones, MD Jr, Popel, AS, Koehler, RC, Traystman, RJ, Zeger, SL. Hemodilution causes size-dependent constriction of pial arterioles in the cat. Am J Physiol 1989; 257 (Part 2): H912–H917.
31. Cabrales, P, Tsai, AG. Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions. Am J Physiol Heart Circ Physiol 2006; 291: H2445–H2452.
32. Tsai, AG, Acero, C, Nance, PR, et al. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol 2005; 288: H1730–H1739.
33. Cooke, JP, Stamler, J, Andon, N, Davies, PF, McKinley, G, Loscalzo, J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990; 259 (Part 2): H804–H812.
34. Pohl, U, Herlan, K, Huang, A, Bassenge, E. EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. Am J Physiol 1991; 261 (Part 2): H2016–H2023.
35. Celermajer, DS, Sorensen, KE, Gooch, VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–1115.
36. de Wit, C, Schafer, C, von Bismarck, P, Bolz, SS, Pohl, U. Elevation of plasma viscosity induces sustained NO-mediated dilation in the hamster cremaster microcirculation in vivo. Pflugers Arch 1997; 434: 354–361.
37. Wilcox, CS, Deng, X, Doll, AH, Snellen, H, Welch, WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 1993; 44: 430–435.
38. Lopez Ongil, SL, Saura, M, Lamas, S, Rodriguez Puyol, M, Rodriguez Puyol, D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp Nephrol 1996; 4: 37–42.
39. Wang, XQ, Vaziri, ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894–899.
40. Gidding, SS, Stockman, JA 3rd. Erythropoietin in cyanotic heart disease. Am Heart J 1988; 116 (Part 1): 128–132.
41. Tyndall, MR, Teitel, DF, Lutin, WA, Clemons, GK, Dallman, PR. Serum erythropoietin levels in patients with congenital heart disease. J Pediatr 1987; 110: 538–544.
42. Ogunshola, OO, Djonov, V, Staudt, R, Vogel, J, Gassmann, M. Chronic excessive erythrocytosis induces endothelial activation and damage in mouse brain. Am J Physiol Regul Integr Comp Physiol 2006; 290: R678–R684.
43. Belhassen, L, Pelle, G, Sediame, S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97: 1584–1589.
44. Gillespie, JS, Sheng, H. Influence of haemoglobin and erythrocytes on the effects of EDRF, a smooth muscle inhibitory factor, and nitric oxide on vascular and non-vascular smooth muscle. Br J Pharmacol 1988; 95: 1151–1156.
45. Rimar, S, Gillis, CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993; 88: 2884–2887.
46. Rich, GF, Roos, CM, Anderson, SM, Urich, DC, Daugherty, MO, Johns, RA. Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung. J Appl Physiol 1993; 75: 1278–1284.
47. Madsen, PL, Scheuermann Freestone, M, Neubauer, S, Channon, K, Clarke, K. Haemoglobin and flow-mediated vasodilation. Clin Sci (Lond) 2006; 110: 467–473.
48. Anand, IS, Chandrashekhar, Y, Wander, GS, Chawla, LS. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 1995; 25: 1402–1407.
49. Defouilloy, C, Teiger, E, Sediame, S, et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am J Respir Crit Care Med 1998; 157 (Part 1): 1452–1460.
50. Giannattasio, C, Piperno, A, Failla, M, Vergani, A, Mancia, G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension 2002; 40: 74–77.
51. Oldershaw, PJ, Sutton, MG. Haemodynamic effects of haematocrit reduction in patients with polycythaemia secondary to cyanotic congenital heart disease. Br Heart J 1980; 44: 584–588.
52. Rosenthal, A, Nathan, DG, Marty, AT, Button, LN, Miettinen, OS, Nadas, AS. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation 1970; 42: 297–308.
53. Gladwin, MT, Lancaster, JR Jr, Freeman, BA, Schechter, AN. Nitric oxide’s reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003; 9: 496–500.
54. Gross, SS, Lane, P. Physiological reactions of nitric oxide and hemoglobin: a radical rethink. Proc Natl Acad Sci USA 1999; 96: 9967–9969.
55. Han, TH, Pelling, A, Jeon, TJ, Gimzewski, JK, Liao, JC. Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier. Biochim Biophys Acta 2005; 1723: 135–142.
56. Liu, X, Samouilov, A, Lancaster, JR Jr, Zweier, JL. Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance. J Biol Chem 2002; 277: 26194–26199.
57. Liao, JC, Hein, TW, Vaughn, MW, Huang, KT, Kuo, L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A 1999; 96: 8757–8761.
58. Kim-Shapiro, DB, Schechter, AN, Gladwin, MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006; 26: 697–705.
59. Bonetti, PO, Pumper, GM, Higano, ST, Holmes, DR Jr, Kuvin, JT, Lerman, A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137–2141.
60. Andreassen, AK, Kvernebo, K, Jorgensen, B, Simonsen, S, Kjekshus, J, Gullestad, L. Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation. Am Heart J 1998; 136: 320–328.
61. Katz, SD, Hryniewicz, K, Hriljac, I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111: 310–314.
62. Pohl, U, Holtz, J, Busse, R, Bassenge, E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8: 37–44.
63. Ramsey, MW, Goodfellow, J, Jones, CJ, Luddington, LA, Lewis, MJ, Henderson, AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 1995; 92: 3212–3219.
64. Maiorana, A, O’Driscoll, G, Dembo, L, et al. Effect of aerobic and resistance exercise training on vascular function in heart failure. Am J Physiol Heart Circ Physiol 2000; 279: H1999–H2005.
65. Hambrecht, R, Hilbrich, L, Erbs, S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000; 35: 706–713.
66. Adatia, I, Kemp, GJ, Taylor, DJ, Radda, GK, Rajagopalan, B, Haworth, SG. Abnormalities in skeletal muscle metabolism in cyanotic patients with congenital heart disease: a 31P nuclear magnetic resonance spectroscopy study. Clin Sci (Lond) 1993; 85: 105–109.
67. Miall-Allen, VM, Kemp, GJ, Rajagopalan, B, Taylor, DJ, Radda, GK, Haworth, SG. Magnetic resonance spectroscopy in congenital heart disease. Heart 1996; 75: 614–619.
68. Oechslin, E, Kiowski, W, Schindler, R, Bernheim, A, Julius, B, Brunner-La Rocca, HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005; 112: 1106–1112.
69. Ferreiro, CR, Chagas, AC, Carvalho, MH, et al. Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease: a novel pathophysiological adaptive mechanism. Circulation 2001; 103: 2272–2276.
70. Toporsian, M, Govindaraju, K, Nagi, M, Eidelman, D, Thibault, G, Ward, ME. Downregulation of endothelial nitric oxide synthase in rat aorta after prolonged hypoxia in vivo. Circ Res 2000; 86: 671–675.
71. Armstead, WM. Opioids and nitric oxide contribute to hypoxia-induced pial arterial vasodilation in newborn pigs. Am J Physiol 1995; 268 (Part 2): H226–H232.
72. Nase, GP, Tuttle, J, Bohlen, HG. Reduced perivascular PO2 increases nitric oxide release from endothelial cells. Am J Physiol Heart Circ Physiol 2003; 285: H507–H515.
73. Pape, D, Beuchard, J, Guillo, P, Allain, H, Bellissant, E. Hypoxic contractile response in isolated rat thoracic aorta: role of endothelium, extracellular calcium and endothelin. Fundam Clin Pharmacol 1997; 11: 121–126.
74. Wolff, B, Lodziewski, S, Bollmann, T, Opitz, CF, Ewert, R. Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. Am Heart J 2007; 153: 1088 e1–7.
75. Karakantza, M, Giannakoulas, NC, Zikos, P, et al. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 2004; 79: 253–259.
76. Lessiani, G, Dragani, A, Falco, A, Fioritoni, F, Santilli, F, Davi, G. Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patients. Br J Haematol 2009; 145: 538–540.
77. Neunteufl, T, Heher, S, Stefenelli, T, Pabinger, I, Gisslinger, H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354–359.
78. Michiels, C, Arnould, T, Remacle, J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000; 1497: 1–10.
79. Ten, VS, Pinsky, DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002; 8: 242–250.
80. Malek, AM, Jackman, R, Rosenberg, RD, Izumo, S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 1994; 74: 852–860.
81. Horigome, H, Murakami, T, Isobe, T, Nagasawa, T, Matsui, A. Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis. Thromb Res 2003; 112: 223–227.
82. Territo, MC, Perloff, JK, Rosove, MH, Moake, JL, Runge, A. Acquired Von Willebrand factor abnormalities in adults with congenital heart disease: dependence upon cardiopulmonary pathophysiological subtype. Clin Appl Thromb Hemost 1998; 4: 257–261.
83. de PS, Soares R, Maeda, NY, Bydlowski, SP, Lopes, AA. Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome. Cardiol Young 2005; 15: 504–513.
84. Starnes, SL, Duncan, BW, Kneebone, JM, et al. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J Thorac Cardiovasc Surg 2000; 119: 534–539.
85. Niwa, K, Perloff, JK, Bhuta, SM, et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001; 103: 393–400.
86. Dedkov, EI, Perloff, JK, Tomanek, RJ, Fishbein, MC, Gutterman, DD. The coronary microcirculation in cyanotic congenital heart disease. Circulation 2006; 114: 196–200.
87. Fyfe, A, Perloff, JK, Niwa, K, Child, JS, Miner, PD. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol 2005; 96: 283–290.
88. Perloff, JK. The coronary circulation in cyanotic congenital heart disease. Int J Cardiol 2004; 97 (Suppl 1): 79–86.
89. Mansour, AM, Bitar, FF, Traboulsi, EI, et al. Ocular pathology in congenital heart disease. Eye 2005; 19: 29–34.
90. Petersen, RA, Rosenthal, A. Retinopathy and papilledema in cyanotic congenital heart disease. Pediatrics 1972; 49: 243–249.
91. Chugh, R, Perloff, JK, Fishbein, M, Child, JS. Extramural coronary arteries in adults with cyanotic congenital heart disease. Am J Cardiol 2004; 94: 1355–1357.
92. Crowe, RJ, Kohner, EM, Owen, SJ, Robinson, DM. The retinal vessels in congenital cyanotic heart disease. Med Biol Illus 1969; 19: 95–99.
93. Kohner, EM, Allen, EM, Saunders, KB, Emery, VM, Pallis, C. Electroencephalogram and retinal vessels in congenital cyanotic heart disease before and after surgery. BMJ 1967; 4: 207–210.
94. Harino, S, Motokura, M, Nishikawa, N, Fukuda, M, Sasaoka, A, Grunwald, JE. Chronic ocular ischemia associated with the Eisenmenger’s syndrome. Am J Ophthalmol 1994; 117: 302–307.
95. Eperon, G, Johnson, M, David, NJ. The effect of arterial PO2 on relative retinal blood flow in monkeys. Invest Ophthalmol 1975; 14: 342–352.
96. Ames, A 3rd. Energy requirements of CNS cells as related to their function and to their vulnerability to ischemia: a commentary based on studies on retina. Can J Physiol Pharmacol 1992; 70 (Suppl): S158–S164.
97. Ahmed, J, Pulfer, MK, Linsenmeier, RA. Measurement of blood flow through the retinal circulation of the cat during normoxia and hypoxemia using fluorescent microspheres. Microvasc Res 2001; 62: 143–153.
98. Bosch, MM, Merz, TM, Barthelmes, D, et al. New insights into ocular blood flow at very high altitudes. J Appl Physiol 2009; 106: 454–460.
99. Wangsa-Wirawan, ND, Linsenmeier, RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol 2003; 121: 547–557.
100. Linsenmeier, RA, Braun, RD. Oxygen distribution and consumption in the cat retina during normoxia and hypoxemia. J Gen Physiol 1992; 99: 177–197.
101. Bosch, MM, Barthelmes, D, Merz, TM, et al. High incidence of optic disc swelling at very high altitudes. Arch Ophthalmol 2008; 126: 644–650.
102. Rennie, D, Morrissey, J. Retinal changes in Himalayan climbers. Arch Ophthalmol 1975; 93: 395–400.
103. Wiedman, M. High altitude retinal hemorrhage. Arch Ophthalmol 1975; 93: 401–403.
104. Shults, WT, Swan, KC. High altitude retinopathy in mountain climbers. Arch Ophthalmol 1975; 93: 404–408.
105. Droma, Y, Hanaoka, M, Basnyat, B, et al. Symptoms of acute mountain sickness in Sherpas exposed to extremely high altitude. High Alt Med Biol 2006; 7: 312–314.
106. Clarke, C, Duff, J. Mountain sickness, retinal haemorrhages, and acclimatisation on Mount Everest in 1975. BMJ 1976; 2: 495–497.
107. Wilson, MH, Newman, S, Imray, CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009; 8: 175–191.
108. Hammond, CJ, Chauhan, DS, Stanford, MS. Pulmonary hypertension and diffuse macular edema responsive to acetazolamide. Arch Ophthalmol 1998; 116: 1535–1536.
109. Van Camp, G, Renard, M, Verougstraete, C, Bernard, R. Ophthalmologic complications in primary pulmonary hypertension. Chest 1990; 98: 1543–1544.
110. Kety, SS, Schmidt, CF. The effects of altered arterial tensions of carbon dioxide and oxygen on cerebral blood flow and cerebral oxygen consumption of normal young men. J Clin Invest 1948; 27: 484–492.
111. Lennox, WG, Gibbs, EL. The blood flow in the brain and the leg of man, and the changes induced by alteration of blood gases. J Clin Invest 1932; 11: 1155–1177.
112. De Schweinitz, GE, Woods, AC. Concerning the ocular symptoms of erythremia (chronic polycythemia vera), with special reference to the fundus picture. Trans Am Ophthalmol Soc 1925; 23: 90–105.
113. Feman, SS, Stein, RS. Waldenstrom’s macroglobulinemia, a hyperviscosity manifestation of venous stasis retinopathy. Int Ophthalmol 1981; 4: 107–112.
114. Nagy, F. Changes in the fundus caused by polycythaemia. Br J Ophthalmol 1950; 34: 380–384.
115. Morley, MG, Heier, JS. Venous obstructive disease of the retina. In: Yanoff M, Duker JS (eds). Yanoff and Duker: Ophthalmology, 3rd edn. Mosby, St. Louis, MO, 2008; 597–601.
116. Tsutsumi, A. Retinopathy in cyanotic congenital heart disease. Jpn J Clin Ophthalmol 1983; 37: 933.
117. Michelson, G, Welzenbach, J, Pal, I, Harazny, J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol 2001; 23: 327–335.
118. Michelson, G, Patzelt, A, Harazny, J. Flickering light increases retinal blood flow. Retina 2002; 22: 336–343.
119. Wong, TY, Islam, FM, Klein, R, et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 2006; 47: 2341–2350.
120. Klein, R, Klein, BE, Knudtson, MD, Wong, TY, Tsai, MY. Are inflammatory factors related to retinal vessel caliber? The Beaver Dam eye study. Arch Ophthalmol 2006; 124: 87–94.
121. Ikram, MK, de Jong, FJ, Vingerling, JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004; 45: 2129–2134.
122. Wong, TY, Kamineni, A, Klein, R, et al. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med 2006; 166: 2388–2394.
123. Wong, TY, Klein, R, Sharrett, AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The atherosclerosis risk in communities study. JAMA 2002; 287: 1153–1159.
124. Wong, TY, Klein, R, Couper, DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis risk in communities study. Lancet 2001; 358: 1134–1140.
125. Wang, JJ, Liew, G, Wong, TY, et al. Retinal vascular calibre and the risk of coronary heart disease-related death. Heart 2006; 92: 1583–1587.
126. Wong, TY, Klein, R, Nieto, FJ, et al. Retinal microvascular abnormalities and 10-year cardiovascular mortality: a population-based case–control study. Ophthalmology 2003; 110: 933–940.
127. Kawagishi, T, Matsuyoshi, M, Emoto, M, et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999; 19: 2509–2516.
128. Delles, C, Michelson, G, Harazny, J, Oehmer, S, Hilgers, KF, Schmieder, RE. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004; 35: 1289–1293.
129. Hida, K, Wada, J, Yamasaki, H, et al. Cyanotic congenital heart disease associated with glomerulomegaly and focal segmental glomerulosclerosis: remission of nephrotic syndrome with angiotensin converting enzyme inhibitor. Nephrol Dial Transplant 2002; 17: 144–147.
130. Fujimoto, Y, Matsushima, M, Tsuzuki, K, et al. Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor. Clin Nephrol 2002; 58: 95–102.
131. Fujita, N, Manabe, H, Yoshida, N, et al. Inhibition of angiotensin-converting enzyme protects endothelial cell against hypoxia/reoxygenation injury. Biofactors 2000; 11: 257–266.
132. Walther, T, Olah, L, Harms, C, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16: 169–176.
133. Creager, MA, Roddy, MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499–505.
134. O’Driscoll, G, Green, D, Maiorana, A, Stanton, K, Colreavy, F, Taylor, R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33: 1506–1511.
135. Glynn, RJ, Danielson, E, Fonseca, FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851–1861.
136. Phornphutkul, C, Rosenthal, A, Nadas, AS, Berenberg, W. Cerebrovascular accidents in infants and children with cyanotic congenital heart disease. Am J Cardiol 1973; 32: 329–334.